RESUMEN
Successful long-term treatment of hypertension must include consideration of individual patients' life-style interfaced with the potential for adverse drug events. In a postmarketing surveillance study, 30,515 patients received captopril monotherapy and were evaluated by 7792 physicians. Mean systolic and diastolic blood pressures were reduced 17 and 11 mm Hg, respectively. Mean diastolic blood pressure was reduced 10% for patients with mild hypertension; larger mean reductions were noted for patients with moderate (16.5%) and severe (21.5%) hypertension. Captopril therapy was equally effective in all races (white, Hispanic, and black patients), age groups, and in isolated instances of systolic hypertension. Only 4.9% of patients reporting an adverse event required discontinuation of therapy. Headache (1.8%) and dizziness (1.6%) were the most frequently reported adverse events. Quality-of-life measures improved.
Asunto(s)
Captopril/uso terapéutico , Hipertensión/tratamiento farmacológico , Calidad de Vida , Adulto , Anciano , Captopril/efectos adversos , Esquema de Medicación , Femenino , Humanos , Estilo de Vida , Masculino , Persona de Mediana EdadAsunto(s)
Antihipertensivos/efectos adversos , Hidroclorotiazida/efectos adversos , Hipertensión/tratamiento farmacológico , Triantereno/efectos adversos , Factores de Edad , Antihipertensivos/uso terapéutico , Ensayos Clínicos como Asunto , Combinación de Medicamentos/efectos adversos , Combinación de Medicamentos/uso terapéutico , Femenino , Humanos , Hidroclorotiazida/uso terapéutico , Hiperpotasemia/inducido químicamente , Hipopotasemia/inducido químicamente , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Triantereno/uso terapéutico , Estados Unidos , Uremia/inducido químicamenteRESUMEN
Beta-adrenergic blocking drugs are gaining acceptance as initial therapy for patients with mild to moderate hypertension. In a postmarketing surveillance study, 5,190 hypertensive patients received timolol maleate monotherapy and were evaluated by 1,355 physicians. A total of 1,057 patients did not complete the study: 28% of these patients experienced an adverse event. Mean systolic and diastolic blood pressure readings were reduced 20 and 13 mm Hg, respectively. Mean diastolic blood pressure was reduced 11% for patients with mild hypertension; larger mean reductions were noted for patients with moderate (17%) and severe hypertension (22%). The effect in black and elderly patients was less than in other groups. Although 22% of all patients experienced an adverse event, less than 2.2% of all patients experienced events related to beta-adrenergic blockade, ie, respiratory difficulty, heart failure, bradycardia, and cold extremities. Fatigue, dizziness, and nausea were the most frequently reported adverse events requiring discontinuation of therapy. Timolol monotherapy is a well-tolerated and effective treatment for a broad range of hypertensive patients.
Asunto(s)
Hipertensión/tratamiento farmacológico , Timolol/uso terapéutico , Adulto , Anciano , Presión Sanguínea/efectos de los fármacos , Femenino , Estudios de Seguimiento , Humanos , Hipertensión/fisiopatología , Masculino , Persona de Mediana Edad , Pulso Arterial/efectos de los fármacos , Timolol/efectos adversosRESUMEN
A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of hydrochlorothiazide, administered twice daily for one month to hypertensive patients. Data on 9,037 patients were collected by 1,455 participating physicians. Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of timolol-hydrochlorothiazide therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being fatigue, dizziness, and weakness. Treatment in 590 patients was discontinued because of adverse events.